Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|July 1, 1984
Simultaneous modeling of bopindolol kinetics and dynamicsR Platzer, R L Galeazzi, W Niederberger, et al.
European Journal of Clinical Pharmacology|January 1, 1991
Pharmacokinetic investigation of oral and i.v. dihydroergotamine in healthy subjectsP A Wyss, J Rosenthaler, E Nüesch, et al.
British Journal of Clinical Pharmacology|July 1, 1986
Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic modelJ Grevel, J Brownell, J L Steimer, et al.
International Journal of Nuclear Medicine and Biology|January 1, 1984
Immunoassay of ergotamine and dihydroergotamine using a common 3H-labelled ligand as tracer for specific antibody and means to overcome experienced pitfallsJ Rosenthaler, H Munzer, R Voges, et al.
Therapeutic Drug Monitoring|June 1, 1987
A new radioimmunoassay of thioridazine and its comparison with a high performance liquid chromatographic method and another radioimmunoassayB S Chakraborty, E M Hawes, J Rosenthaler, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormoneE del Pozo, K Schlüter, E Nüesch, et al.
British Journal of Clinical Pharmacology|October 1, 1978
Plasma bromocriptine levels, clinical and growth hormone responses in ParkinsonismP Price, A Debono, J D Parkes, et al.
Clinical Chemistry|February 1, 1988
Specific 3H radioimmunoassay with a monoclonal antibody for monitoring cyclosporine in bloodP E Ball, H Munzer, H P Keller, et al.
British Journal of Clinical Pharmacology|January 1, 1986
Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindololW H Aellig, E Nüesch, G Engel, et al.
Diabetologia|November 1, 1989
Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patientsA J Scheen, J Gillet, J Rosenthaler, et al.
Pageof 3